Link between GLP-1 drugs and risk of blinding disease
Image credit: cdc via Unsplash
Recent research published in the journal JAMA Ophthalmology has indicated a potential link between GLP-1 drugs, such as Wegovy and Ozempic, and an increased risk of a severe eye condition that can lead to blindness. These drugs, commonly prescribed for diabetes management and weight loss, may be associated with a complication characterized by abnormal blood vessel growth in the retina which can severely impair vision. Healthcare professionals are advised to monitor patients closely for any visual symptoms and consider comprehensive eye exams as part of the care plan for those using these medications.
Source
Hathaway JT, Shah MP, Hathaway DB, et al. Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide. JAMA Ophthalmol. Published online July 03, 2024. doi:10.1001/jamaophthalmol.2024.2296
Additional Reading